Hélène M. Faessel - Concepedia

Author

Hélène M. Faessel

Also Known As

Faessel, H., H Faessel, H M Faessel, H. Faessel, H.M. Faessel, Helene Faessel, Helene M Faessel, Helene M. Faessel, Hélène Faessel, Hélène M Faessel

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Takeda (United States)Pfizer (United States)Millennium Engineering and Integration (United States)Takeda (Japan)Sylvester Comprehensive Cancer Center

About

Hélène M. Faessel is an author at Takeda (United States) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	12	525
2	Natural Sciences	2	2	47
3	Social Sciences	2	2	140
4	Engineering	1	1	29
5	Health Sciences	1	1	29

Hélène M. Faessel

Publications

2.1K

Citations

H-Index

Page 1

	Year	Citations
Pevonedistat (<scp>MLN</scp>4924), a First‐in‐Class <scp>NEDD</scp>8‐activating enzyme inhibitor, in patients with acute myeloid leukaemia and myelodysplastic syndromes: a phase 1 study Ronan Swords, Harry P. Erba, Daniel J. DeAngelo, British Journal of Haematology	2015	234
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML Ronan Swords, Steven Coutré, Michael B. Maris, Blood	2018	198
Phase I Study of the Novel Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (MLN4924) in Patients with Relapsed/Refractory Multiple Myeloma or Lymphoma Jatin J. Shah, Andrzej Jakubowiak, Owen A. O’Connor, Clinical Cancer Research	2015	188
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors John Sarantopoulos, Geoffrey I. Shapiro, Roger B. Cohen, Clinical Cancer Research	2015	163
A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma Shailender Bhatia, Anna C. Pavlick, Peter D. Boasberg, Investigational New Drugs	2016	112
Single‐Dose Pharmacokinetics of Varenicline, a Selective Nicotinic Receptor Partial Agonist, in Healthy Smokers and Nonsmokers Hélène M. Faessel, Bill J. Smith, Megan Gibbs, The Journal of Clinical Pharmacology	2006	104
Multiple‐Dose Pharmacokinetics of the Selective Nicotinic Receptor Partial Agonist, Varenicline, in Healthy Smokers Hélène M. Faessel, Megan Gibbs, David J. Clark, The Journal of Clinical Pharmacology Dose LevelTobacco ControlHealthy Adult SmokersAddictionDrug Discovery	2006	93
Orexin 2 receptor–selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients Rebecca Evans, Haruhide Kimura, Robert Alexander, Proceedings of the National Academy of Sciences Sleep DisordersNarcolepsy PhenotypePharmacotherapyNarcolepsy Type 1Experimental Pharmacology	2022	85
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors A. Craig Lockhart, Todd M. Bauer, Charu Aggarwal, Investigational New Drugs	2018	73
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial David P. Dearnaley, Daniel R. Saltzstein, John E. Sylvester, European Urology	2020	71

Page 1